USL311 is a potent, selective, orally bioavailable CXCR4 antagonist, with potential antineoplastic activity.
USL311 binds to CXCR4, prevente the binding of stromal-cell derived factor-1 (SDF-1 or CXCL12) to CXCR4 and inhibiting CXCR4 activation, decreases proliferation and migration of CXCR4-expressing tumor cells.
CXCR4, a chemokine receptor belonging to the G protein-coupled receptor (GPCR) family, plays an important role in chemotaxis and angiogenesis, and is upregulated in several tumor cell types.
